中国批准施塔波基巴特(Stapokibart), 这是抗过敏的新药物, 标志着中国首次批准国内IL-4Rα抗体。 China approves Stapokibart, a new drug for allergies, marking the country's first domestic IL-4Rα antibody approval.

中国国家医疗产品管理局已经批准Stapokibart(Stapokibart), 这是Keymed生物科学的新药, 用于治疗季节性过敏鼻炎。 China's National Medical Products Administration has approved Stapokibart, a new drug by Keymed Biosciences, to treat seasonal allergic rhinitis. 该药物是一种抗IL-4Rα单克隆抗体,在第三阶段的一项研究中发现,它有效控制了流鼻鼻涕、鼻塞和喷嚏等症状。 The drug, an anti-IL-4Rα monoclonal antibody, was found to be effective in controlling symptoms like runny nose, nasal congestion, and sneezing in a phase III study. 这是中国批准的第一种国内制造的IL-4Rα抗体药物,在试验中表现出良好的安全性和有效性。 It is the first domestically made IL-4Rα antibody drug approved in China, showing good safety and efficacy in trials.